olanzapine

P=N/A, N=3000, Recruiting, Boryung Pharmaceutical Co., Ltd

P1, N=20, Completed, University Hospital, Basel, Switzerland | Recruiting --> Completed

Molecular docking demonstrated strong binding affinities between olanzapine and these targets, with docking scores ranging from - 5.3 to - 8.8 kilocalories per mole (kcal/mol). These findings suggest that olanzapine, as an antipsychotic, may alleviate acute agitation symptoms by modulating signaling pathways associated with neuroinflammation and neuroplasticity, providing a basis for further research into its mechanism of action in neuropsychiatric disorders.

This review covers key investigational therapies developed over the past five years, with a focus on agents targeting Growth Differentiation Factor 15 (GDF-15), including ponsegromab, AV-380, and NGM120. Additional agents include ghrelin receptor agonists (e.g. anamorelin), anabolic/catabolic modulators (ACM-001), and cannabinoids (ART27.13). The evolving role of low-dose olanzapine is also discussed in the 2023 ASCO guideline update...The lack of standardized endpoints, heterogeneity of the syndrome, and absence of FDA-approved treatments remain major barriers to treatment implementation. Multimodal strategies combining pharmacological treatment with nutritional and rehabilitative support are likely to define future therapeutic success.

P4, N=24, Terminated, The Guthrie Clinic | N=104 --> 24 | Trial completion date: Nov 2029 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2028 --> Jul 2025; Study stopped due to lower than expected accrual.

P3, N=92, Not yet recruiting, The affiliated people's hospital of Ningbo University; The affiliated people's hospital of Ningbo University

P4, N=420, Not yet recruiting, Wang Chenggang(Study sponsor); Shanxi Provincial Hospital of Traditional Chinese Medicine / Shanxi Provincial Institute of Traditional Chinese Medicin

The CFRGs risk prognosis model can effectively predict patients' immune infiltration and immunotherapy response, providing a new reference basis for individualized treatment plans for COAD patients.

P3, N=222, Recruiting, Affiliated Hospital of Qinghai University

P1, N=50, Completed, University of Sao Paulo

P2, N=66, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Jun 2031 --> Nov 2031 | Trial primary completion date: Jun 2030 --> Nov 2030

P2, N=120, Recruiting, Boryung Pharmaceutical Co., Ltd | Initiation date: Feb 2025 --> May 2025